During the Ranexa® (ranolazine, A. Menarini) official launch symposium, renowned speaker Professor John Camm spoke on how ranolazine, a novel anti-anginal agent, could play a role in managing chronic stable angina (CSA). The session was followed by a lecture by Dr David Quek, who discussed the value of optimal medical therapy (OMT) in the management of CSA.
Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.
Dr. Wook Bum Pyun, Prof. Giuseppe Mancia, Assoc Prof. Tan Ru San, 20161108000000
Although there is some controversy surrounding the use of beta-blockers in patients with hypertension, third-generation agents such as nebivolol (Nebilet®, Menarini) function via unique mechanisms that improve upon the tolerability and haemodynamic profiles of older agents. At a recent Menarini-sponsored symposium held during the International Society of Hypertension 2016 meeting, Dr Wook Bum Pyun from the Ewha Womans University, Seoul, Korea, Professor Giuseppe Mancia from the University of Milano-Bicocca, Italy, and Associate Professor Tan Ru San from the National Heart Centre, Singapore, discussed these novel mechanisms and their effects on clinical outcomes.
Prof. Michael Weber, Prof. Giuseppe Mancia, Dr. Nelson Abelardo, 20161108000000
The use of beta-blockers in patients with cardiovascular (CV) disorders is somewhat controversial. However, many of the problems associated with traditional first- and second-generation beta-blockers may not be applicable to third-generation beta-blockers. Professor Michael Weber from the State University of New York, US, Professor Giuseppe Mancia from the University of Milano-Bicocca, Italy, and Dr Nelson Abelardo from the University of the Philippines, discussed the role of beta-blockers in managing patients with hypertension and chronic heart failure (CHF) at a recent Menarini-sponsored symposium held during the International Society of Hypertension 2016 meeting in Seoul, Korea, highlighting the potential benefits associated with newer beta-blockers such as nebivolol (Nebilet®, Menarini).
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.